Puma Biotechnology, Inc. (NASDAQ:PBYI) defied analyst predictions to release its first-quarter results, which were...
Q1 2020 Puma Biotechnology Inc Earnings Call
New Strong Buy Stocks for May 13th
As of late, it has definitely been a great time to be an investor in Puma Biotechnology, Inc. (PBYI).
On May 8, 2020, Puma Biotechnology reported inducement restricted stock unit awards granted in April 2020 under Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology, Inc. (PBYI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Puma Biotechnology, which saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 75 to 90. As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotechnology released its financial results for the first quarter ended March 31, 2020 on May 7, 2020.
Puma Biotechnology's licensing partner CANbridge Pharmaceuticals has received regulatory approval to market NERLYNX (neratinib) in Mainland China.
Puma Biotechnology and Bixink Therapeutics have signed a license agreement in which Bixink will commercialize Puma's drug NERLYNX in South Korea.
Retailers are facing a variety of issues from weaker in-store sales to laying off workers. Yahoo Finance’s Reggie Wade joins the On The Move panel to discuss what investors should expect ahead of Nike's earnings report.
Good afternoon, and welcome to Puma's conference call to discuss our financial results for the first quarter of 2020. Joining me on the call today are Alan Auerbach, Chief Executive Officer, President and Chairman of the Board of Puma Biotechnology; and Maximo Nougues, Chief Financial Officer.
Alan Auerbach, CEO of Puma Biotechnology, will present a corporate update at the BofA Securities Virtual 2020 Health Care Conference on May 13, 2020.
Puma Biotechnology, Inc.'s (NASDAQ:PBYI): Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the...
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Puma Biotech (PBYI) delivered earnings and revenue surprises of 45.57% and 16.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech's (PBYI) loss and revenues better estimates in the first quarter of 2020.
Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health through innovative precision biomarker approaches, today announced the appointment of Jay M. Moyes as Chief Financial Officer. Mr. Moyes joins Sera Prognostics as it transitions from rigorous scientific and groundbreaking clinical stage company into a rapidly growing commercial organization. For more than two decades, Jay Moyes has served in C-level executive and board positions of both private and public companies.
On March 25, 2020, Puma Biotechnology reported an inducement award granted to Jeff Ludwig as part of his agreement to enter into employment with Puma.